Welcome to our dedicated page for Emmaus Life Sciences SEC filings (Ticker: EMMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Emmaus Life Sciences filings document formal disclosures for a commercial-stage biopharmaceutical company focused on Endari® for sickle cell disease. Recent Form 8-K reports cover operating results and financial condition, material agreements involving Endari commercialization and supply, and capital-structure actions such as convertible note exchanges and common stock issuance.
The filing record also includes governance disclosures on director resignations, board appointments, audit committee membership, and compensatory arrangements. Emmaus filings identify its public-company context, securities-registration status, exhibit filings, liquidity, derivative liabilities, debt restructuring, and other matters tied to its regulated biopharmaceutical business.
Emmaus Life Sciences, Inc. (EMMA) discloses that CEO and director Willis C. Lee, through retirement accounts, reported a series of open-market purchases of common stock. Between May 30, 2025 and August 31, 2026, entities for his benefit bought an aggregate 530,767 shares at weighted average prices generally ranging from about $0.01 to $0.075 per share, all reported as indirect ownership.
Emmaus Life Sciences, Inc. reported sharply improved results for the three and six months ended June 30, 2026, driven by a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Net revenues for the quarter rose 124% to $6.3 million from $2.8 million a year earlier, primarily from recognition of upfront and royalty revenue under the NIT license, partly offset by lower direct Endari sales. Total operating expenses fell to $2.1 million from $3.0 million, mainly due to transferring the sales force to NIT, resulting in income from operations of $3.8 million versus a $0.4 million loss.
Quarterly net income was $1.3 million, or $0.02 per basic share, compared with a net loss of $1.1 million, or ($0.02) per share in 2025. For the six-month period, net revenues were $8.3 million and the company recorded a net loss of $2.0 million, improved from a $3.5 million loss a year earlier. Cash and cash equivalents were $2.8 million at June 30, 2026, up from $2.1 million at December 31, 2025. The balance sheet shows total assets of $16.4 million against total liabilities of $82.5 million, resulting in a stockholders’ deficit of $66.2 million. The company also references previously disclosed doubt about its ability to continue as a going concern in its risk factors.
Emmaus Life Sciences, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026. Net revenues rose to $6.3 million from $2.8 million a year earlier, driven mainly by U.S. Endari® sales and a new license and supply relationship with NeoImmuneTech (NIT). Quarterly net income was $1.3 million, compared with a net loss of $1.1 million in the prior-year quarter, while the first half still showed a net loss of $2.0 million.
Despite better operating performance, the balance sheet remains highly leveraged. Cash and cash equivalents were $2.8 million and total assets $16.4 million, against total liabilities of $82.5 million and a stockholders’ deficit of $66.2 million. The company discloses a working capital deficit of $60.1 million and significant notes payable and convertible debt, along with pledged investments and "sale of future receipts" financing arrangements.
Management states there is substantial doubt about the ability to continue as a going concern over the next 12 months without restructuring or refinancing existing indebtedness and raising additional capital, noting that no such arrangements are currently in place.
Emmaus Life Sciences reported first-quarter 2026 results showing lower revenue but reduced operating expenses. Net revenues for the three months ended March 31, 2026 were $2.0 million, down 18% from $2.4 million a year earlier, mainly from a 33% decline in U.S. sales amid generic L-glutamine competition, partly offset by a 446% increase in sales in the MENA region.
Total operating expenses fell to $2.6 million from $3.2 million, improving loss from operations to $0.8 million compared with $1.0 million. However, higher interest and derivative-related costs drove other expense up to $2.5 million, increasing net loss to $3.3 million, or $0.05 per share, versus $2.3 million, or $0.04 per share. Cash and cash equivalents were $1.1 million at March 31, 2026, with total liabilities of $86.6 million and a stockholders’ deficit of $67.9 million.
Emmaus Life Sciences reported a challenging quarter for the three months ended March 31, 2026. Revenue was $1.98 million, down from $2.41 million a year earlier, while net loss widened to $3.34 million from $2.33 million. Basic and diluted loss per share was $0.05 on 70.2 million weighted-average shares.
Total assets were $18.7 million against total liabilities of $86.6 million, resulting in a stockholders’ deficit of $67.9 million and cash of only $1.07 million. Management discloses a working capital deficit of $64.5 million and states there is substantial doubt about the company’s ability to continue as a going concern without restructuring debt or raising additional capital.
U.S. Endari® revenue declined sharply, partially offset by growth in international sales. The company continues to rely on high-interest debt, convertible notes and related‑party loans while managing a sizeable convertible bond investment in Telcon. Subsequent to quarter end, its U.S. Endari® license and supply arrangements with NeoImmuneTech became effective, shifting future U.S. revenue toward supply sales and royalties.
Emmaus Life Sciences, Inc. director Du Henry Huy filed an initial Form 3 reporting his status as a director of the company. The filing shows no reportable transactions, no reported common stock holdings, and no derivative securities positions, with all transaction and holding counts recorded as zero.
Emmaus Life Sciences, Inc. appointed Henry H. Du to its Board of Directors by written consent on April 16, 2026, filling the vacancy created by the recent resignation of Jon Kuwahara. He is also expected to replace Mr. Kuwahara as the sole member of the Board’s Audit Committee.
Mr. Du, age 48, is Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc., a biopharmaceutical company, and is a Certified Public Accountant with a Bachelor of Arts degree from Claremont McKenna College. Emmaus states there are no family relationships or related-party transactions requiring disclosure, and that he will be compensated like its other directors.
Emmaus Life Sciences, Inc. reported that director Jon Kuwahara resigned from its board. The resignation was dated April 13, 2026 and becomes effective April 15, 2026. The company also identified a cover page interactive data file as Exhibit 104 embedded within the inline XBRL document.
Emmaus Life Sciences reported full-year 2025 results showing sharply lower sales but improved operating performance. Net revenue was $12.5 million, down 25% from $16.7 million in 2024, mainly due to U.S. competition from generic L-glutamine, partly offset by higher sales in the MENA region.
Total operating expenses fell 34% to $11.4 million from $17.3 million, turning a $0.2 million income from operations versus a $1.9 million operating loss a year earlier. However, other expense rose to $7.5 million from $4.5 million, driven by higher loss on debt extinguishment and interest expense and lower gains on restructured debt.
Emmaus recorded a 2025 net loss of $7.2 million (or $0.12 per share) compared with a $6.5 million net loss (or $0.10 per share) in 2024. At December 31, 2025, cash and equivalents were $2.1 million versus $1.4 million a year earlier, while total liabilities were $85.0 million and stockholders’ deficit was $63.6 million. Management is shifting U.S. strategy through a license and exclusive distribution arrangement with NeoImmuneTech and emphasizes international growth for Endari.
Emmaus Life Sciences, Inc. reports continued operating losses and severe liquidity pressure, with a comprehensive loss of $7.2 million in 2025 and a working capital deficit of $61.3 million. The auditor included a going concern paragraph as the company depends on restructuring or refinancing significant debt and raising new capital.
Emmaus’ business centers on its only product, Endari, for sickle cell disease, now facing U.S. generic competition after orphan exclusivity expired in July 2024. A new License and Exclusive Distribution Agreement with NeoImmuneTech (NIT) would shift U.S. commercialization to NIT, but the Effective Date depends on regulatory and other conditions and may never occur. Outside the U.S., Emmaus is expanding Endari in the MENA region, but relies on single‑source suppliers and packagers and must navigate longer reimbursement cycles and geopolitical risks.